Overvægt kliniske forsøg i Mississippi
11 studier for Overvægt søger deltagere på steder i Mississippi.
Byer i Mississippi
Officiel studietekst (engelsk)
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Dynamed Clinical Research, LP d/b/a DM Clinical Research, Gulfport
RekruttererFase 3
Alder 6 til 17 · Alle køn · Opdateret 24. sep. 2026 · NCT06672549A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Fayette
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07784270Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Jackson Heart Clinic, Jackson
- Cardiology Associates of North Mississippi, Tupelo
RekruttererFase 3
Alder 45 til 99 · Alle køn · Opdateret 22. sep. 2026 · NCT07037433A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Gulfport
- AURORA-1 Clinical Site, Jackson
- AURORA-1 Clinical Site, Olive Branch
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 16. sep. 2026 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Gulfport
- AURORA-2 Clinical Site, Jackson
- AURORA-2 Clinical Site, Olive Branch
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 16. sep. 2026 · NCT07743450A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Olive Branch Family Medical Center, Olive Branch
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 14. sep. 2026 · NCT07351058A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- DelRicht Research at Gulfport Memorial, Gulfport
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 14. sep. 2026 · NCT07351045A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Gulfport
- ACCOMPLISH-2 Research Site, Ridgeland
RekruttererFase 3Frivillige med god helbredstilstand velkomne
Alder 18 til 79 · Alle køn · Opdateret 11. sep. 2026 · NCT07654374Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Prime Health and Wellness Sky Clinical Research Network Group, Fayette
RekruttererFase 3
Alder 18 til 99 · Alle køn · Opdateret 3. sep. 2026 · NCT07684235Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Sky Integrative Medical Center, Ridgeland
RekruttererFase 3
Alder 18 til 99 · Alle køn · Opdateret 27. aug. 2026 · NCT07575399Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Gulfport
- ACCOMPLISH-1 Research Site, Ridgeland
RekruttererFase 3
Alder 18 til 79 · Alle køn · Opdateret 10. aug. 2026 · NCT07654361Fra ClinicalTrials.gov, data hentet 4. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.